Partners Biogen and Eisai shook up the drug industry this month with the surprising revelation that an in-development drug for Alzheimer’s disease showed unprecedented promise in a clinical trial.
And that’s about all they said. On Wednesday, the companies will divulge the details on the drug, called BAN2401. Here’s your guide to how experts are approaching what could be the biggest Alzheimer’s news in years.
About the Author Reprints
